Avizakimab, formerly known as BOS161721, represents a innovative therapeutic approach to treating autoimmune diseases . This biological agent selectively targets interleukin-18 , a key signaling molecule https://lorivpwn767827.aboutyoublog.com/54547082/avizakimab-a-detailed-investigation-into-bos161721-s-capability